Deceuninck Geneviève, Brousseau Nicholas, Lefebvre Brigitte, Quach Caroline, Tapiero Bruce, Bui Yen-Giang, Desjardins Michael, De Wals Philippe
Axe Maladies infectieuses et immunitaires, Centre de recherche du CHU de Québec - Université Laval, Québec, QC, Canada; Direction des risques biologiques, Institut National de Santé Publique du Québec, Québec, QC, Canada.
Laboratoire de santé publique du Québec, Institut national de santé publique du Québec, Sainte-Anne-de-Bellevue, QC, Canada.
Vaccine. 2024 Dec 2;42(26):126379. doi: 10.1016/j.vaccine.2024.126379. Epub 2024 Sep 26.
In the province of Quebec, Canada, a 2 + 1 dose pneumococcal conjugate vaccine (PCV) program for children was implemented in 2004. PCV7, PCV10, PCV13 and a mixed PCV10/PCV13 schedule were sequentially used without catch-up. The effectiveness of vaccination schedules to prevent serotype 19A invasive pneumococcal disease (IPD) in <5-year-old children was estimated by the indirect cohort method during 2009-2023. A total of 248 19A IPD cases and 457 IPD controls were included in the analysis. Adjusted vaccine effectiveness (VEa) for ≥1 dose was 57 % [95 %CI: -1 %,82 %] for PCV10 and 62 % [16 %,83 %] for PCV13. VEa for 3 doses was 69 % [17 %,88 %] for PCV10, 76 % [39 %,90 %] for PCV13 and 86 % [64 %,95 %] for the 2PCV10 + 1PCV13 schedule. Protection provided by the PCV10-only schedule tended to be of lower magnitude compared to the two other schedules. The mixed PCV10 + PCV13 schedule showed a protection against 19A IPD at least comparable to that of 3 PCV-13 doses.
在加拿大魁北克省，2004年实施了针对儿童的2 + 1剂量肺炎球菌结合疫苗（PCV）计划。先后使用了PCV7、PCV10、PCV13和混合的PCV10/PCV13接种程序，且未进行补种。在2009年至2023年期间，采用间接队列法评估了不同接种程序对5岁以下儿童预防19A血清型侵袭性肺炎球菌病（IPD）的有效性。分析共纳入248例19A IPD病例和457例IPD对照。对于PCV10，≥1剂的调整后疫苗有效性（VEa）为57% [95%CI：-1%，82%]；对于PCV13，VEa为62% [16%，83%]。对于PCV10，3剂的VEa为69% [17%，88%]；对于PCV13，VEa为76% [39%，90%]；对于2PCV10 + 1PCV13接种程序，VEa为86% [64%，95%]。与其他两种接种程序相比，仅使用PCV10接种程序提供的保护作用往往较小。混合的PCV10 + PCV13接种程序对19A IPD的保护作用至少与3剂PCV-13相当。
